Temporary restraining order, in effect since Nov. 13, barring FDA from approving additional ANDAs for generic versions of Mylan's Maxzide, lifted by New York Eastern Federal District Court Nov. 24. Court denied American Therapeutic's motion for preliminary injunction seeking revocation of ANDA exclusivity granted to Vitarine for the antihypertensive ("The Pink Sheet" Nov. 9, p. 3). New Jersey Federal Court also ruled in favor of FDA in a Nov. 20 hearing on a complaint against the exclusivity grant brought by Barr Labs.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?